SAGE Therapeutics (SAGE) Misses Q2 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. EXPE
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. SNAP

Go back to SAGE Therapeutics (SAGE) Misses Q2 EPS by 21c

Sage Therapeutics (SAGE) PT Raised to $95 at Needham & Company

August 4, 2017 7:27 AM EDT

Needham & Company raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $95.00 (from $82.00) while maintaining a Buy rating.

Analyst Danielle Brill commented, "Sage plans to report data from seven trials by YE17. Expected first in 3Q are results from the Brexanolone Phase 3 SRSE trial which... More